Market Report

The month in one paragraph 

October is a Q4 lock-in month — three market situations should anchor near-term planning. Peru’s fish oil catastrophe has produced a historic $2,500/MT fishmeal spot price — roughly 25% above 2023-2024 levels — with the second anchovy season opening November 1 into the same Coastal El Niño conditions that broke the first. IFFO reports Q1 2026 fishmeal production down 38% YoY. Whey has taken a step-change higher: USDA Sept 24 reports WPC 34% at $2.05-$3.10/lb (mostly $2.35-$2.70), WPC 80% mid-$10s to mid-$11s with buyers finally pausing to build inventory, and WPI still in the $14s. The August monthly average WPC 34% at $2.1371/lb is the highest in the USDA series. Choline AD/CVD has a hard date: DOC set the CVD preliminary determination deadline at November 23, with the AD prelim still on December 1 — Chinese choline exposure should be reviewed against this November planning anchor. On the margins: ocean freight softens ahead of Golden Week (WCI at $4,468, -1% WoW), the yuan holds strong at 6.7256 (USD -5.6% YoY), and the rupee has weakened past RBI’s 96 defense line to 96.17. Net: Q4 planning should center on securing fish oil allocation, locking whey pricing where possible, and modeling choline duty scenarios before Nov 23.

Regulatory landscape:

Q4 hinges on three November dates: the Peru second-season opening on Nov 1 (fish oil availability), the choline CVD preliminary determination on Nov 23 (China-origin duty timeline), and the choline AD preliminary determination on Dec 1. The one bright note: WPC 80% buyers are finally pausing to build inventory, the first tangible break in the whey shortage story.

Market movers – the big stories 

Peru Fish Oil — November 1 Second Season Is the Whole Q4 Story — URGENT ALLOCATION

What happened:

Peru’s second anchovy season opens November 1 into an already-broken market. First season landed only ~451,000 MT of the 1.914M MT quota (23.6%) before the June 10 shutdown. Fishmeal spot has hit a historic $2,500/MT — roughly 25% above 2023-2024 levels. IFFO reports Q1 2026 fishmeal production down 38% YoY among member nations. Peru’s Central Reserve Bank projects a 6.6% contraction in the fishing sector for full-year 2026 with the second season anticipated to face pronounced pressure from persisting Coastal El Niño (FEN) conditions.

Why it happened: The math is now inescapable. Peru = 20% of global fishmeal/fish oil supply. First season delivered a quarter of an already-reduced quota. Second season starts into the same warm-water conditions that broke the first. El Niño forecast to persist into early 2027. Refiners have already allocated Q4 to existing contracts; new spot buyers face limited-to-no availability. This is not a pricing negotiation — it’s an allocation triage.

What we expect: Refined EPA/DHA offers stay firm 25-40% above pre-crisis levels through Q1 2027, with upside risk if the second season disappoints early. Krill and algal DHA substitution flows continue accelerating; algal DHA capacity expansion announcements likely in Q4. Watch November 15-30 second-season landings reports as the leading indicator for Q1 2027 fish oil availability.

Confidence: High. Invalidation: Second season lands >75% of TAC in November-December with normal juvenile ratios; FEN downgraded in October ENSO update.

Whey — WPC 34% Range Blows Out to $2.05-$3.10, WPC 80% Buyers Blink — CRITICAL SHORTAGE

What happened: USDA Sept 24 report: WPC 34% range $2.05-$3.10/lb (mostly $2.35-$2.70), materially higher than the August $2.00-$2.19 report. WPC 80% trades mid-$10s to mid-$11s per lb — but activity has slowed as buyers stop chasing and producers build inventory. WPI still in the $14s with a firmer tone than WPC 80%. August monthly average WPC 34% at $2.1371/lb — the highest in the USDA series.

Why it happened: Two different dynamics have emerged. WPC 34% is going vertical — the range has widened dramatically, some offers exceed the reported range, and feed-grade has rebased higher on scarcity. WPC 80% has hit a buyer resistance wall: the mid-$10s to $11s is where reformulation math becomes compelling for many CMs, and volume buyers are stepping back. WPI stays tighter than WPC 80% because clinical and premium sports nutrition applications can absorb the cost.

What we expect: WPC 34% keeps grinding higher through Q4 as feed and secondary applications compete with dairy-diverted whey streams. WPC 80% may stabilize or briefly soften on demand destruction but stays historically elevated. WPI holds premium. Reformulation to pea/rice/soy/casein/egg/yeast protein accelerates further at the mass-market end. Confidence: High. Invalidation: Major dairy processor announces capacity return; GLP-1 usage plateau + real demand destruction on high-protein products.

Choline AD/CVD — November 23 CVD Prelim Date Set, Countdown Begins — REGULATORY EVENT

What happened: DOC formally set the new CVD preliminary determination deadline at November 23, 2026 — a 67-day extension from the original September 17 date, announced in a September 1 Federal Register notice. The AD preliminary determination still tracks December 1. ITC affirmed injury indication August 10. Once affirmative preliminary determinations issue, importers must post cash deposits on covered imports from the publication date forward.

Why it happened: Petitioner BCP Ingredients requested the extension citing time required to identify mandatory respondents and complexity of programs under investigation. Commerce approved under statutory authority extending the window to 130 days after initiation. This is procedural — the case is moving forward, not slowing down.

What we expect: Customers using Chinese choline should treat November 23 as the operative planning date. Model duty scenarios in the 30-60% range for both animal nutrition and dietary supplement applications. Qualify alternative origins (Indian, European) now — a scramble in late November is worse than a plan in October. Confidence: Medium-High. Invalidation: DOC issues negative preliminary determination; petitioner withdraws; scope narrowed to exclude nutraceutical applications.

Ocean Freight — Softening Continues Into Golden Week — SOFTENING

What happened: Drewry WCI at $4,468 (Sept 24, -1% WoW). Route mix has diverged: Shanghai-LA firmed +2% to $7,838 and Shanghai-NY held stable at $10,373, while Shanghai-Genoa fell 5% to $3,835 and Shanghai-Rotterdam fell 4% to $3,485. 15 blank sailings announced for the next week, up from 9, indicating carriers protecting capacity ahead of China’s Golden Week (early October).

Why it happened: Golden Week is historically a slower shipping period, so carriers are managing capacity down proactively. Suez Canal transits rose from 41 (Week 37) to 48 (Week 38), adding effective Asia-Europe capacity and softening those lanes. Transpacific holds firm on absolute levels but not accelerating. Panama Canal water constraints, Rhine River low water, German labor issues, Red Sea security all remain background variables.

What we expect: Rates soften further into and through Golden Week (roughly Oct 1-8), then likely a modest post-holiday bounce as Chinese factories restart. WCI likely stays in $3,800-$4,600 range through year-end unless there’s a geopolitical event. Customers with Q1 2027 arrivals should be locking rates now. Confidence: Medium. Invalidation: Major Middle East escalation; Panama Canal fully closes; unexpected US tariff action.

Early Signals – not yet moving, but watching

Q4 Colostrum Allocation Conversations Arriving

SPINS retail growth continues at extraordinary rates and dairy processors are scaling colostrum capacity, but investment lags demand. Q4 2026 is when explicit allocation conversations arrive. Customers building colostrum-based portfolios should have supply relationships locked before Thanksgiving, not chasing in December.

Algal DHA Capacity Expansion Announcements Likely

As the fish oil crisis stretches into a fourth quarter of allocation, algal DHA producers (Corbion/DSM, ADM, Fermentalg) all have commercial incentive to signal expansion investments. First expansion announcement is the signal about long-term marine-omega supply strategy — worth understanding the substitution economics before that news breaks.

Indian Botanicals 2026-27 Harvest Data Due

IMD first-stage forecast was 92% of LPA. October harvest data confirms whether the below-normal monsoon materialized. Ashwagandha, turmeric, boswellia, bacopa all exposed. Customers on annual contracts should be monitoring closely — offers likely to firm through Q4 if harvest data disappoints.

Vietnam Section 301 +12.5% — Precedent for Broader Rate Adjustments

USTR imposed an additional +12.5% Section 301 forced-labor tariff on Vietnamese goods effective July 24. This is the template for country-specific adjustments still possible for Cambodia, Bangladesh, Thailand, and others under active USTR investigation. Customers with Southeast Asian sourcing should model +10-25% country-specific overlays on Section 301 base rates.

Nootropic Caffeine Forms Gaining Ground

Paraxanthine (faster/more focused) and Deura9 (longer duration) continuing to gain traction in cognitive performance positioning. Standard caffeine anhydrous still dominant but premium nootropic forms building real volume. Formulators building differentiated pre-workout, focus, or hybrid energy SKUs should be evaluating these forms now.

Golden Week Freight Softening Window

Chinese Golden Week (Oct 1-8) traditionally softens ocean freight before a post-holiday bounce. WCI is likely to see its cyclical low in the two weeks after Golden Week before Q4 restocking firms it again. Customers with Q1 2027 arrivals should be locking rates in that window.

Trend pulse

Rising — Worth Building Around

Peru fish oil substitutes — krill oil, algal DHA: Substitution flows becoming the primary driver, not marginal.

Colostrum: Q4 allocation conversations arriving; 2,454% growth in hair/skin/nails per SPINS.

Creatine (broad category): SPINS +71.9% MULO growth; broadening to women, older consumers, cognitive positioning.

Electrolytes (sodium chloride, potassium citrate, mag citrate): SPINS +21.9% YoY category growth.

Casein/caseinate: GLP-1 satiety positioning; Silk High-Protein launch validated the angle.

Whey alternatives — pea, rice, soy, egg, yeast: WPC 80% buyer resistance is accelerating reformulation.

Cellular energy / NAD+ ingredients — NMN, CoQ10/ubiquinol: Continuing shift to mainstream wellness.

Marine collagen: Continues premium over bovine on bioavailability positioning.

Natural colorants — lycopene, spirulina, sodium copper chlorophyllin, annatto: FDA phase-out driving structural reformulation.

Branded clinical extracts — KSM-66, Magtein: Premium positioning wins over commodity.

Declining — Losing Steam

Generic bovine collagen at parity pricing: Margin compression persists.

Magnesium oxide: Chelated forms eroding share (per SPINS category data).

CBD: Continued drift downward.

Pure L-ascorbic acid in skincare: Stabilized derivatives (SAP, AA-2G) gaining share.

Synthetic food colors: Structural decline as FDA phase-out proceeds.

Traditional pill formats: 70% pill fatigue; gummies, drink mixes, chewables gaining.

Aspartame: Demand recovery slow; supply ample.

Strategic considerations by category 

Sports nutrition:

• Reformulation pathways from whey are now table stakes. Formulators still on 100% whey formulas heading into Q1 2027 launches should have blended pea/rice/soy/casein/egg/yeast alternatives at cost-model stage this month.
• Fish oil allocation should be secured for Q1 2027 now, not in December. Krill and algal DHA are viable substitution paths with different EPA:DHA ratios — worth pre-qualifying both.
• Creatine and electrolyte demand supports blended-format innovation (RTDs, gummies, chewables). Q4 2026 launches emphasizing creatine + electrolytes + protein combined formulations are the emerging pattern.
• Casein/caseinate positions strongly for GLP-1-adjacent muscle-preservation SKUs (slow-release amino acid story).

Beauty, skincare, and aging:

• Colostrum supply relationships worth locking before Thanksgiving — Q4 allocation conversations are arriving.
• Marine collagen premium over bovine holds; positioning story remains bioavailability and dietary flexibility.
• NMN quality verification (COAs, patent clarity, NDI notification per company) is the market differentiator, not price.
• Stabilized vitamin C derivatives (SAP, MAP, AA-2G) continue to gain share versus pure L-ascorbic in cosmetic applications.

GLP-1 users and weight management:

• Muscle preservation remains the strategic frame; whey, casein, pea, soy, collagen, taurine, creatine, leucine, HMB, magnesium, and B12 all have roles.
• Silk High-Protein launch signals broader food industry entering GLP-1-adjacent formulations. Casein-forward positioning has been validated at scale.
• Fiber-maxxing parallel trend (beta-glucan, inulin, psyllium, resistant starches) is complementary, not competitive.
• Format matters: cold-soluble, clear-textured, juice-like formats consistently outperform legacy powder-and-shake formats with GLP-1 users.

Botanicals and AYUSH ingredients:

• India USD advantage strengthened as the rupee weakened past 96 — worth locking long-cycle ingredient contracts while the advantage holds.
• 2026-27 monsoon harvest data due through October will determine Q4 offer levels on ashwagandha, turmeric, boswellia, and bacopa.
• Branded clinical extracts (KSM-66 ashwagandha, Magtein L-threonate) continue to command premium; commoditized variants losing share.

Food and beverage:

• Choline sourcing decisions should be finalized before November 23. Model duty scenarios in the 30-60% range for Chinese origin; qualify alternative origins (India, EU) now.
• FDA synthetic color phase-out reformulation is urgent for anything shipping in 2027. Lycopene, beta-carotene, spirulina, sodium copper chlorophyllin, annatto — all in demand.
• Section 301 regime settled at 10-12.5% baseline. Vietnam already at +12.5% country-specific — precedent for further country adjustments over the coming quarters.
• US AD landscape continues on citric acid, glycine, calcium citrate, erythritol, gluconate salts, lysine — with choline joining Q4/Q1 2027.

Methodology & sourcing

This report synthesizes information from public sources including USDA Dairy Market News, Peru PRODUCE/IMARPE releases via SeafoodSource, Aquafeed, and Aquaculture Magazine, Drewry World Container Index updates, USTR notices, Federal Register filings, ITC publications, IMD forecasts, FDA regulatory actions, TradingEconomics FX data, NutraIngredients-USA, Nutritional Outlook, SPINS retail data, IFFO, GOED, and earnings/industry commentary from Glanbia, FrieslandCampina, ADM, AlzChem, Danone, and BCP Ingredients.

The Ingredient Market Trends section reflects directional reads based on public sources and trade press as of the month of publication. For current Vitajoy pricing on specific ingredients and volumes, please contact your Vitajoy account representative.

Forward-looking calls are deliberately specific so they can be scored. Confidence levels and invalidation conditions are disclosed. We track our calls quarterly and adjust methodology based on what we get right and what we miss — credibility compounds over time.